Gregg Tavares serves as Principal Scientist I at Cambrex, where he leverages over 25 years of extensive experience in analytical chemistry within the pharmaceutical research and development landscape. His role as an analytical project lead positions him at the forefront of supporting clients in generating...
Gregg Tavares serves as Principal Scientist I at Cambrex, where he leverages over 25 years of extensive experience in analytical chemistry within the pharmaceutical research and development landscape. His role as an analytical project lead positions him at the forefront of supporting clients in generating clinical and registration batches for Phase III candidates. In this capacity, Gregg acts as the single point of contact, ensuring seamless communication and coordination of all analytical activities between external clients and internal teams. His expertise encompasses a wide array of analytical technologies, including UV spectroscopy and Karl Fischer titration, which he adeptly applies to small molecule and active pharmaceutical ingredient (API) development.
Gregg's proficiency in method development, validation, and transfer is critical to the success of projects at Cambrex. He has a proven track record of managing complex projects, ensuring compliance with industry standards and regulatory requirements. His skills in dissolution testing and adherence to USP guidelines further enhance the quality and reliability of the analytical data generated. As a project manager, Gregg is not only focused on delivering results but also on fostering collaborative relationships with clients and stakeholders, which is essential for navigating the intricacies of drug development.
In addition to his technical acumen, Gregg's ability to streamline processes and implement standard operating procedures (SOPs) contributes to the efficiency and effectiveness of the R&D and manufacturing support functions at Cambrex. His commitment to excellence and continuous improvement makes him a valuable asset in the fast-paced and ever-evolving pharmaceutical industry.
